Lack of GP130 expression in hepatocytes attenuates tumor progression in the DEN model

Cell Death and Disease

Volumn 6, Issue 3, 2015, Pages

  Hatting, M ^a   Spannbauer, M ^a   Peng, J ^a   Al Masaoudi, M ^a   Sellge, G ^a   Nevzorova, Y A ^a   Gassler, N ^a   Liedtke, C ^a   Cubero, F J ^a   Trautwein, C ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DIETHYLNITROSAMINE; GLYCOPROTEIN GP 130; HISTONE H2AX; INTERLEUKIN 11; INTERLEUKIN 6; MALONALDEHYDE; MYELOPEROXIDASE; ONCOSTATIN M; REACTIVE OXYGEN METABOLITE; SMAD2 PROTEIN; SMAD3 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER GROWTH; CANCER PROGNOSIS; CELL FATE; CONTROLLED STUDY; DOUBLE STRANDED DNA BREAK; EXPERIMENTAL HEPATITIS; EXPERIMENTAL LIVER INJURY; FEMALE; HISTONE PHOSPHORYLATION; LIPID PEROXIDATION; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; MALE; MOUSE; NEUTROPHIL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR VOLUME; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DNA DAMAGE; DRUG EFFECTS; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; IMMUNOBLOTTING; INFLAMMATION; KNOCKOUT MOUSE; METABOLISM;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CYTOKINE RECEPTOR GP130; DIETHYLNITROSAMINE; DNA DAMAGE; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HEPATOCYTES; IMMUNOBLOTTING; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; ONCOSTATIN M; OXIDATIVE STRESS; STAT3 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR;

EID: 84988837650     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.590     Document Type: Article

References (59)

1. Severi T, van Malenstein H, Verslype C, van Pelt JF Tumor initiation and progression in hepatocellular carcinoma: risk factors, classification, and therapeutic targets. Acta Pharmacol Sin 31: 1409-1420.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
3. Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/ gp130 signaling. J Clin Invest 2011; 121: 3375-3383.
4. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2002; 2: 364-371.
5. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007; 7: 429-442.
6. Yoshida K, Taga T, Saito M, Suematsu S, Kumanogoh A, Tanaka T et al. Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc Natl Acad Sci USA 1996; 93: 407-411.
7. Silver JS, Hunter CA. gp130 at the nexus of inflammation, autoimmunity, and cancer. J Leukoc Biol 2010; 88: 1145-1156.
8. Boulanger MJ, Chow DC, Brevnova EE, Garcia KC. Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science 2003; 300: 2101-2104.
9. Stahl N, Boulton TG, Farruggella T, Ip NY, Davis S, Witthuhn BA et al. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. Science 1994; 263: 92-95.
10. Lutticken C, Wegenka UM, Yuan J, Buschmann J, Schindler C, Ziemiecki A et al. Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science 1994; 263: 89-92.
11. Streetz KL, Wustefeld T, Klein C, Kallen KJ, Tronche F, Betz UA et al. Lack of gp130 expression in hepatocytes promotes liver injury. Gastroenterology 2003; 125: 532-543.
12. Streetz KL, Tacke F, Leifeld L, Wustefeld T, Graw A, Klein C et al. Interleukin 6/gp130-dependent pathways are protective during chronic liver diseases. Hepatology 2003; 38: 218-229.
13. Sander LE, Obermeier F, Dierssen U, Kroy DC, Singh AK, Seidler U et al. Gp130 signaling promotes development of acute experimental colitis by facilitating early neutrophil/ macrophage recruitment and activation. J Immunol 2008; 181: 3586-3594.
14. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007; 317: 121-124.
15. Lee JS, Chu IS, Mikaelyan A, Calvisi DF, Heo J, Reddy JK et al. Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet 2004; 36: 1306-1311.
16. Stucki M, Clapperton JA, Mohammad D, Yaffe MB, Smerdon SJ, Jackson SP. MDC1 directly binds phosphorylated histone H2AX to regulate cellular responses to DNA doublestrand breaks. Cell 2005; 123: 1213-1226.
17. Kang MA, So EY, Simons AL, Spitz DR, Ouchi T. DNA damage induces reactive oxygen species generation through the H2AX-Nox1/Rac1 pathway. Cell Death Dis 2012; 3: e249.
18. Cook PJ, Ju BG, Telese F, Wang X, Glass CK, Rosenfeld MG. Tyrosine dephosphorylation of H2AX modulates apoptosis and survival decisions. Nature 2009; 458: 591-596.
19. Liu Y, Fuchs J, Li C, Lin J. IL-6, a risk factor for hepatocellular carcinoma: FLLL32 inhibits IL-6-induced STAT3 phosphorylation in human hepatocellular cancer cells. Cell Cycle 2010; 9: 3423-3427.
20. Feghali CA, Wright TM. Cytokines in acute and chronic inflammation. Front Biosci 1997; 2: d12-d26.
21. Sommer J, Effenberger T, Volpi E, Waetzig GH, Bernhardt M, Suthaus J et al. Constitutively active mutant gp130 receptor protein from inflammatory hepatocellular adenoma is inhibited by an anti-gp130 antibody that specifically neutralizes interleukin 11 signaling. J Biol Chem 2012; 287: 13743-13751.
22. Heindryckx F, Colle I, Van Vlierberghe H. Experimental mouse models for hepatocellular carcinoma research. Int J Exp Pathol 2009; 90: 367-386.
23. Wang H, Yang ES, Jiang J, Nowsheen S, Xia F. DNA damage-induced cytotoxicity is dissociated from BRCA1's DNA repair function but is dependent on its cytosolic accumulation. Cancer Res 2010; 70: 6258-6267.
24. Waris G, Ahsan H. Reactive oxygen species: role in the development of cancer and various chronic conditions. J Carcinog 2006; 5: 14.
25. He G, Karin M. NF-kappaB and STAT3 - key players in liver inflammation and cancer. Cell Res 2011; 21: 159-168.
26. He G, Yu GY, Temkin V, Ogata H, Kuntzen C, Sakurai T et al. Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell 17: 286-297.
27. Gu FM, Li QL, Gao Q, Jiang JH, Zhu K, Huang XY et al. IL-17 induces AKT-dependent IL-6/ JAK2/STAT3 activation and tumor progression in hepatocellular carcinoma. Mol Cancer 10: 150.
28. Miyakoshi M, Yamamoto M, Tanaka H, Ogawa K. Serine 727 phosphorylation of STAT3: an early change in mouse hepatocarcinogenesis induced by neonatal treatment with diethylnitrosamine. Mol Carcinog 2014; 53: 67-76.
29. Hosui A, Kimura A, Yamaji D, Zhu BM, Na R, Hennighausen L. Loss of STAT5 causes liver fibrosis and cancer development through increased TGF-{beta} and STAT3 activation. J Exp Med 2009; 206: 819-831.
30. Mueller KM, Kornfeld JW, Friedbichler K, Blaas L, Egger G, Esterbauer H et al. Impairment of hepatic growth hormone and glucocorticoid receptor signaling causes steatosis and hepatocellular carcinoma in mice. Hepatology 2011; 54: 1398-1409.
31. Migone TS, Lin JX, Cereseto A, Mulloy JC, O'Shea JJ, Franchini G et al. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science 1995; 269: 79-81.
32. Moriggl R, Sexl V, Piekorz R, Topham D, Ihle JN. Stat5 activation is uniquely associated with cytokine signaling in peripheral T cells. Immunity 1999; 11: 225-230.
33. Moriggl R, Topham DJ, Teglund S, Sexl V, McKay C, Wang D et al. Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity 1999; 10: 249-259.
34. Lee TK, Poon RT, Yuen AP, Man K, Yang ZF, Guan XY et al. Rac activation is associated with hepatocellular carcinoma metastasis by up-regulation of vascular endothelial growth factor expression. Clin Cancer Res 2006; 12: 5082-5089.
35. He G, Yu GY, Temkin V, Ogata H, Kuntzen C, Sakurai T et al. Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell 2010; 17: 286-297.
36. Di Maio M, De Maio E, Morabito A, D'Aniello R, De Feo G, Gallo C et al. Hormonal treatment of human hepatocellular carcinoma. Ann N Y Acad Sci 2006; 1089: 252-261.
37. Xu J, Attisano L. Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor beta signaling by targeting Smads to the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 2000; 97: 4820-4825.
38. Wu WY, Li J, Wu ZS, Zhang CL, Meng XL. STAT3 activation in monocytes accelerates liver cancer progression. BMC Cancer 2011; 11: 506.
39. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576.
40. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008; 48: 1312-1327.
41. Howlett M, Judd LM, Jenkins B, La Gruta NL, Grail D, Ernst M et al. Differential regulation of gastric tumor growth by cytokines that signal exclusively through the coreceptor gp130. Gastroenterology 2005; 129: 1005-1018.
42. Ernst M, Najdovska M, Grail D, Lundgren-May T, Buchert M, Tye H et al. STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J Clin Invest 2008; 118: 1727-1738.
43. Rebouissou S, Amessou M, Couchy G, Poussin K, Imbeaud S, Pilati C et al. Frequent inframe somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 2009; 457: 200-204.
44. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007; 7: 41-51.
45. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9: 798-809.
46. Johnson C, Han Y, Hughart N, McCarra J, Alpini G, Meng F. Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer. Transl Gastrointest Cancer 1: 58-70.
47. Kalra M, Mayes J, Assefa S, Kaul AK, Kaul R. Role of sex steroid receptors in pathobiology of hepatocellular carcinoma. World J Gastroenterol 2008; 14: 5945-5961.
48. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C et al. Stat3 as an oncogene. Cell 1999; 98: 295-303.
49. Bartneck M, Ritz T, Keul HA, Wambach M, Bornemann J, Gbureck U et al. Peptide-functionalized gold nanorods increase liver injury in hepatitis. ACS Nano 2012; 6: 8767-8777.
50. Williams GM, Iatropoulos MJ, Jeffrey AM. Mechanistic basis for nonlinearities and thresholds in rat liver carcinogenesis by the DNA-reactive carcinogens 2-acetylaminofluorene and diethylnitrosamine. Toxicol Pathol 2000; 28: 388-395.
51. Matthews VB, Knight B, Tirnitz-Parker JE, Boon J, Olynyk JK, Yeoh GC. Oncostatin M induces an acute phase response but does not modulate the growth or maturation-status of liver progenitor (oval) cells in culture. Exp Cell Res 2005; 306: 252-263.
52. Li Z, Tuteja G, Schug J, Kaestner KH. Foxa1 and Foxa2 are essential for sexual dimorphism in liver cancer. Cell 2012; 148: 72-83.
53. Lawrence T, Hageman T, Balkwill F. Cancer. Sex, cytokines, and cancer. Science 2007; 317: 51-52.
54. Cubero FJ, Singh A, Borkham-Kamphorst E, Nevzorova YA, Al Masaoudi M, Haas U et al. TNFR1 determines progression of chronic liver injury in the IKKgamma/Nemo genetic model. Cell Death Differ 2013; 20: 1580-1592.
55. Teoh NC, Dan YY, Swisshelm K, Lehman S, Wright JH, Haque J et al. Defective DNA strand break repair causes chromosomal instability and accelerates liver carcinogenesis in mice. Hepatology 2008; 47: 2078-2088.
56. Ito N, Kawata S, Tamura S, Takaishi K, Shirai Y, Kiso S et al. Elevated levels of transforming growth factor beta messenger RNA and its polypeptide in human hepatocellular carcinoma. Cancer Res 1991; 51: 4080-4083.
57. Cohen PA, Koski GK, Czerniecki BJ, Bunting KD, Fu XY, Wang Z et al. STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34pos cells into tumor-competent dendritic cells. Blood 2008; 112: 1832-1843.
58. Yang XP, Ghoreschi K, Steward-Tharp SM, Rodriguez-Canales J, Zhu J, Grainger JR et al. Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat Immunol 2011; 12: 247-254.
59. Betz UA, Bloch W, van den Broek M, Yoshida K, Taga T, Kishimoto T et al. Postnatally induced inactivation of gp130 in mice results in neurological, cardiac, hematopoietic, immunological, hepatic, and pulmonary defects. J Exp Med 1998; 188: 1955-1965.